Effective treatment for lower urinary tract symptoms (LUTS) in men aged 50 or older is associated with a lower risk of death over the next few years reports a study in the October issue of The Journal of Urology, an Official Journal of the American Urological Association.
J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem
Share this article J&J also acquired the remaining global rights for Nanobiotix’s radioenhancer oncology drug, NBTXR3, from LianBio. Image Credit: Michael Vi / Shutterstock. Johnson